Market closedNon-fractional
Vanda Pharmaceuticals/VNDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Ticker
VNDA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Washington, United States
Employees
203
Website
www.vandapharma.com
VNDA Metrics
BasicAdvanced
$358M
Market cap
-
P/E ratio
-$0.09
EPS
0.71
Beta
-
Dividend rate
Price and volume
Market cap
$358M
Beta
0.71
Financial strength
Current ratio
4.708
Quick ratio
4.616
Long term debt to equity
1.197
Total debt to equity
1.64
Management effectiveness
Return on assets (TTM)
-2.43%
Return on equity (TTM)
-0.91%
Valuation
Price to revenue (TTM)
1.993
Price to book
0.66
Price to tangible book (TTM)
0.84
Price to free cash flow (TTM)
-3.075
Growth
Revenue change (TTM)
-30.81%
Earnings per share change (TTM)
-132.49%
3-year revenue growth (CAGR)
-11.11%
3-year earnings per share growth (CAGR)
-45.60%
What the Analysts think about VNDA
Analyst Ratings
Majority rating from 1 analysts.
VNDA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$47M
4.87%
Net income
-$4.1M
70.83%
Profit margin
-8.64%
63.02%
VNDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.12
$0.03
-
-$0.04
-
Expected
$0.08
-$0.13
-$0.04
-$0.09
$0.05
Surprise
50.00%
-123.08%
-
-55.56%
-
VNDA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals (VNDA) has a market cap of $358M as of July 27, 2024.
What is the P/E ratio for Vanda Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vanda Pharmaceuticals (VNDA) stock is 0 as of July 27, 2024.
Does Vanda Pharmaceuticals stock pay dividends?
No, Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Vanda Pharmaceuticals dividend payment date?
Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Vanda Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.